News

GBR401 has been developed completely in-house by Glenmark‘s Biologics Research Centre located in Switzerland, using an advanced technology. GBR 401 targets lymphomas, leukemia’s of B-cell origin and inflammatory

to-BBB is planning to initiate the Phase I/II clinical trial in a few months at three academic hospitals in the Netherlands led by neuro-oncology experts of the Antoni

ANAVEX 2-73 is a new class of oral, disease-modifying drug being studied to potentially treat alzheimer’s disease itself, versus treating its symptoms. The Phase 1 study will evaluate

BioMAP offers insight into human pharmacological and toxicological properties of compounds, including on- and off-target effects, dose responses, and the discrimination of closely related compounds. The Patent no.

The study, a 48-week, global, double-blind, randomized, placebo-controlled trial, involved nearly 300 previously untreated patients infected with the most common form of hepatitis C virus (HCV), the genotype

REALIZE is the final of three clinical trials conducted as part of a global Phase 3 registration program for telaprevir in treatment-naïve and treatment-failure patients with chronic HCV

OMS103HP did not meet the pre-specified endpoints of these studies. No conclusions were made regarding the drug-effect due to confounding factors in the studies. Omeros chairman and chief

The randomised, double-blind, placebo-controlled, parallel-group, multi-centre Phase III study will evaluate the safety and efficacy dexpramipexole in people with familial or sporadic ALS. The study will enroll approximately

The drug has been approved as a treatment for anemia in adults and children six years of age or older, undergoing chronic hemodialysis who are receiving supplemental epoetin